Objectives: This study presents the comparative safety and side effect profiles of buprenorphine and methadone, including gender relationships, from a clinical trial comparing buprenorphine and methadone in the outpatient treatment of opioid dependence.
W hile methadone has been the primary pharmacotherapy for the treatment of opioid addiction in the United States, buprenorphine has been the primary medication used for this indication in France since 1996. Buprenorphine's widespread use in France is in large part due to its ready availability to general practitioners, who can prescribe and treat opioid dependent persons in an officebased setting, in contrast to methadone, which is more tightly regulated there. 1 In 2002 the United States Food and Drug Administration (FDA) approved buprenorphine under Schedule III for the treatment of opioid dependence; this is a less restrictive category than that of methadone. Coupled with The Drug Addiction Treatment Act of 2000, this FDA approval makes buprenorphine the first opioid available to physicians in the U.S. to prescribe in an office-based setting for opioid dependence since the Harrison Narcotic Act of 1914. Clinical trials of buprenorphine have focused primarily on providing efficacy data [2] [3] [4] [5] [6] [7] ;
there has been relatively little systematic evaluation of the safety and side effects of buprenorphine in comparison to methadone. Most such reports have been secondary analyses from outpatient clinical trials of efficacy. For example, in an early clinical trial of 8 mg of daily sublingual buprenorphine solution versus 20 and 60 mg of daily oral methadone, significant differences on reports of decreased appetite, difficulty urinating, anxiety, sedation/drowsiness, and constipation were noted, although there was no consistent pattern as to which medication was associated with elevated symptom reports.
levomethadyl acetate, daily oral methadone, and thrice weekly buprenorphine solution reported the most common side effects across groups were constipation (21%), nausea (8%), and dry mouth (6%); however, there was no analysis of side effects between groups or across time. 7 A more recent clinical trial comparing sublingual buprenorphine tablets to daily oral methadone using flexible dosing reported nearly identical rates of common side effects for both medications: nausea (buprenorphine: 17%; methadone: 16%), bodily pain (buprenorphine: 14%; methadone: 15%), and sweating (buprenorphine: 15%; methadone: 14%). 8 However, the mean doses of medications and time course of these effects were not reported. Several other clinical trials have reported no difference in side effects or adverse effects between buprenorphine and methadone; however, the assessment of these indices is often unclear or relies on spontaneous self-reports of symptoms. 2, 4, 6, 9, 10 Among side effects of buprenorphine, this medication's effects on liver function have been of particular clinical concern. Case reports have documented elevations in liver function tests and more severe hepatic pathology (eg, panlobular necrosis, microvesicular steatosis, and severe hepatitis) in persons taking buprenorphine; however, most of these cases occur in the presence of preexisting liver disease (hepatitis B and/or C), parental use of buprenorphine, and/or concomitant use of potentially hepatotoxic drugs. 11 Three studies using buprenorphine for the treatment of opioid dependence have suggested buprenorphine can be associated with elevated liver function tests (LFTs). The first was a prospective study of 18 subjects maintained on buprenorphine (8 mg daily or every other day); 11 subjects had elevations in serum transaminases. 12 A second retrospective study reported elevations of serum glutamic pyruvic transaminase (SGPT) (median increase was 8.5 u/L) and serum glutamic oxalacetic transaminase (SGOT) (median increase was 9.5 u/L) in persons taking buprenorphine with hepatitis B and/or C compared with buprenorphine-maintained persons without hepatitis. 13 The third study was a large clinical trial (n = 736) comparing 1, 4, 8, and 16 mg of daily buprenorphine. 14 That study reported 14 cases of elevated LFTs that were not dose related. However, in all 3 studies it was not possible to attribute LFT elevations specifically to buprenorphine, in part because there were no non-buprenorphine control groups. In contrast to these findings, an open label clinical trial of 60 subjects (of whom 51 had hepatitis C) compared daily sublingual buprenorphine tablets (mean dose: 7.5 mg) to daily oral methadone (mean dose: 63 mg) and found no significant differences in LFT results, although no data or statistics were presented. 15 Thus, it
remains unclear to what extent buprenorphine affects LFTs, and whether this differs from methadone. Although methadone has not been known to cause liver function abnormalities, most of the reports on the medical safety of methadone were completed years ago when prevalence rates of hepatitis C were not known. [16] [17] [18] [19] [20] This article reports on the comparative safety and side effect profiles of buprenorphine and methadone from a double-blind clinical trial that compared daily sublingual buprenorphine solution with daily oral methadone in the outpatient treatment of opioid dependence. Outcomes for treatment retention, urine results, weekly self-reports, and Addiction Severity Index assessments have been previously reported. 5, 21 Buprenorphine and methadone were equally effective in retaining patients in treatment, and there was no significant difference in rates of opioid-positive urines for the two groups. The present report additionally examines the role of gender in the assessments of safety, as previous reports have suggested that gender may be relevant in studies of buprenorphine efficacy. 22, 23 The results of these analyses, especially with regards to liver function, can be useful in guiding the clinician's determination of how to best use buprenorphine in the office-based treatment of opioid dependence.
METHODS

Participants
Subjects were 164 volunteers, not in substance abuse treatment at the time of application to the study, who were admitted to a short-term opioid treatment-research clinic operated by the Johns Hopkins University Behavioral Pharmacology Research Unit to participate in a randomized double-blind comparison of buprenorphine versus methadone treatment of opioid dependence. Eighty-four patients were randomized to the buprenorphine condition, and 80 to the methadone condition, and there were no significant differences between groups on demographic variables (Table 1) .
Participants were between the ages of 18 and 50 years old, fulfilled diagnostic criteria for opioid dependence using the Structured Clinical Interview for DSM-III-R, 24 and had at least 1 year of intravenous opioid dependence. Participants provided 2 opioidpositive urine samples and underwent extensive medical and psychiatric evaluation prior to study admission. 5, 21 Medical staff not involved in the study as investigators excluded subjects who had a positive pregnancy test, histories of major mental illness (eg, schizophrenia), or significant chronic medical problems. Ineligible applicants were assisted in seeking alternative treatment. The study was approved by the local Institutional Review Board, and written informed consent was obtained from all participants.
Study and Treatment Procedures
Eligible subjects were stratified by race and gender and randomly assigned to either daily sublingual buprenorphine solution or daily oral methadone. The primary period of study intervention was the first 16 weeks of the 26-week study period, when subjects were maintained on buprenorphine or methadone, and results reported here are from this 16-week period. All dosing was double dummy (all subjects received both an oral and a sublingual dosage form) and was supervised daily at the clinic without take-home doses. During the first and second week of treatment subjects were stabilized on either 50 mg of methadone or 8 mg of buprenorphine, and starting in the third week and extending until the sixteenth week of treatment, double-blind dose increases and decreases could occur based on clinical criteria. 5, 21 Participants who missed medication for 3 consecutive days were discharged from study treatment. Mean doses during treatment were 54 mg methadone (range 50-90 mg) and 8.9 mg buprenorphine (range 8-16 mg). During the last 10 weeks of treatment, the week 16 dose was tapered. In addition to receiving study medication, each participant had an individualized treatment plan and goals, weekly individual counseling, and weekly group therapy that focused on relapse prevention. A full-time internist provided onsite medical services. 
Outcome Measures
Liver Function Tests Blood samples were scheduled to be collected from each participant prior to admission and then once every 30 days while in treatment. Samples were tested for SGOT, SGPT, alkaline phosphatase, total bilirubin, albumin, globulin, and total protein (this battery of tests will be referred to as ''liver function tests'' or LFTs). Nursing staff typically made at least 2 attempts to obtain a scheduled blood sample for testing; however, several participants had poor venous access, and staff was unable to obtain samples from all subjects at all times. Eighty-four percent of scheduled LFTs were collected.
Self-Report Side Effects Questionnaire
Participants completed a weekly selfreport form, the Symptom Checklist, asking them to rate the past week severity of 20 symptoms (selected to represent common potential medication side effects): blurred vision, constipation, diarrhea, dizziness/faintness, dreaming more when asleep, dry mouth, headache, heart racing, loss of interest in sex, nausea, often thirsty, ringing in ears, skin rash, sleepy or groggy after medication, tremors/shaking, trouble with sexual performance, trouble swallowing, trouble urinating, upset stomach, and vomiting. Subject ratings could range from 0-4: not at all (0), mild (1), moderate (2), severe (3), and very severe (4). Ninety-seven percent of scheduled reports were completed.
Vital Signs
Subjects were scheduled to have their systolic and diastolic blood pressure (SBP and DBP, respectively), heart rate (HR), oral temperature, and respiratory rate (RR) (these tests will be referred to as ''vital signs'') recorded prior to admission, every 2 weeks for the first 12 weeks of the study, and then once per month for the remainder of the study. Assessments were conducted by nursing staff prior to dosing of medication using a manual blood pressure cuff and stethoscope (for SBP and DBP assessments), manual palpation of the radial artery (for HR assessment), an Ivac thermometer (for temperature assessment), and observation (for RR assessment). Eighty-four percent of scheduled vital sign readings were collected.
Medical Reports
Subjects could meet with medical staff blind to medication assignments if they had a somatic concern to be addressed. When such evaluations occurred, the medical staff filled out a standard medical report form that included sections for describing the concern, ratings for cause of the concern (study drug, concurrent illness, concurrent drug, other known cause), clinical judgment regarding the probability the concern was related to the study drug (definitely, probably, possibly, unknown), clinical evaluation of the medical severity of the problem (mild, moderate, severe), and the outcome. Twenty-seven medical reports were completed during the study.
Data Analysis
Analyses were conducted using 2 different samples: 86 participants who remained in treatment throughout the 16 weeks (the ''retained sample'') and who have been previously described, 21 and the sample of 164 patients that included the 86 subjects who completed the study as well as the remaining 78 subjects who had data collected before they dropped out of treatment (the ''retained plus drop-out sample''). Patterns of missing data were analyzed to determine if missing values differed by medication or gender, and they did not. In addition, the 86 subjects who completed the study were compared with the 78 who dropped out of the study on the demographic variables listed in Table 1 , and the retained subjects differed only in being significantly older than the subjects who droppedout (33.8 versus 31.1 years, P < 0.01).
Liver Function Tests
LFTs were summarized in 4-week blocks (treatment days 15-42, 43-70, 71-98, and 99-126), each spanning the 2 weeks before and 2 weeks after the time the sample was scheduled to be obtained. Because of insufficient sample collections during treatment days 99-126 (65% collected), the first 2 analyses described below included only data from the baseline and first 3 in-treatment time intervals (treatment days 15-42, 43-70, and 71-98), while the last 2 analyses included all time intervals. LFT results were examined 4 ways. The first approach examined data available from the retained plus drop-out sample. Each of the 7 LFTs was coded as abnormal if it exceeded parameters shown in Table 2 ; 87% of the expected data were available for the baseline and first 3 in-treatment intervals. Generalized Estimating Equations (GEE) that can model missing data were used to compare, by medication and gender, the proportions of subjects with an abnormal result at each time interval. Higher order interactions were evaluated, non-significant interactions were removed, and the reduced model results are reported.
The second approach analyzed the preadmission baseline and in-treatment absolute LFT values for the retained sample (n = 86); 94% of expected data were available. These data were not normally distributed. However, because there is no non-parametric test available that allows for analyses with missing values, the data were analyzed with PROC MIXED for repeated measures using 3 factors (medication 3 gender 3 time), understanding that conclusions should be qualified given the non-normality of the data.
The third set of analyses examined the relationship by medication and by gender of the new development of abnormal SGOT and SGPT values since previous studies found elevations in these 2 tests in buprenorphine treated subjects. [12] [13] [14] Subjects who had normal SGOT or SGPT data at baseline and remained in treatment through at least day 71 (n = 90 for SGOT and n = 83 for SGPT) were coded for development of an abnormal SGOT or SGPT value. Of those subjects with new abnormal test values, the day in treatment of the abnormal value, the abnormal value (mean used if multiple abnormal values were found after baseline), the change from baseline to peak abnormal value, and whether the test subsequently normalized were recorded. Results were then compared between medications for SGOT and SGPT separately using Fisher exact test for dichotomous data, 2-tailed t tests for normally distributed continuous data, and Mann-Whitney U tests for non-normally distributed continuous data. Lastly, those subjects who had abnormal baseline SGOT or SGPT test values and subsequent SGOT or SGPT test results available while taking study medication were examined (n = 18 for SGOT and n = 25 for SGPT). The baseline value, the last available test value, the change from baseline to last available value, and whether the test value normalized or not while taking study medication were compared between medications using Fisher exact test for dichotomous data, 2-tailed t tests for normally distributed continuous data, and Mann-Whitney U tests for non-normally distributed continuous data.
Self-Report Side Effects Questionnaire
Rating scores of individual items from the Symptom Checklist were analyzed for the first 16 weeks of treatment using a 3-factor (medication 3 gender 3 time) repeated measures PROC MIXED analysis for those subjects who remained in treatment through the 16 weeks of the study (n = 86). This is the same sub-population of patients examined in the LFT analyses, and like the LFT data, these data were not normally distributed.
Vital Signs
Vital sign results for subjects were summarized at baseline, then in 2-week intervals for the first 12 weeks of the study (treatment days 1-14, 15-28, 29-42, 43-56, 57-70, and 71-84), and in a final 4-week interval (treatment days 85-112) for the last study period. However, since there was a high rate of missing values at the last time point (>40%), analyses used only the baseline time point and the first 6 in-treatment time intervals.
Vital sign results were analyzed 2 ways. The first approach used the retained plus drop-out sample, and coded each vital sign as normal or abnormal using the values shown in Table 2 . Ninety-one percent of expected data was present. Generalized Estimating Equations (GEE) compared the proportions of subjects by medication and gender with an abnormal result at each time interval. Separate analyses were conducted for abnormally high and abnormally low values of systolic and diastolic blood pressure, heart rate, and respiratory rate. Temperature was only characterized as abnormal if elevated.
The second approach analyzed the preadmission and in-treatment absolute vital sign values for the retained sample (n = 86); 92% of expected data was available, however, data were not normally distributed. Like the LFT and Symptom Checklist data, PROC MIXED repeated measures analysis using 3 factors (medication 3 gender 3 time) was completed understanding that conclusions would be qualified by the non-normality of the data.
RESULTS
Liver Function Tests (LFTs)
Retained Plus Drop-Out Sample
The proportion of subjects by gender and medication assignment with abnormal values at pre-admission baseline and at each time interval during treatment was determined. There were no abnormal total bilirubin values, 1 abnormal total protein value in a male taking methadone (which returned to normal at later study points), and 3 abnormal albumin values in 2 male methadone patients (1 value returned to normal at later time points; the second subject did not complete the study and had no subsequent data available). There were 8 abnormal globulin test results in 7 males (3 assigned to methadone and 4 assigned to buprenorphine) that returned to normal in 6 of the subjects; the seventh subject had his abnormal test at baseline and dropped out of the study before further blood tests were drawn. None of these abnormalities in total bilirubin, total protein, albumin, or globulin values produced a statistically significant test result by medication, gender, or time. Table 3 shows the percent of abnormal test results for the remaining 3 LFTs: SGOT, SGPT, and alkaline phosphatase. Results are shown across time by medication and by gender separately since there were no medication 3 gender interactions. SGOT results demonstrated 2 statistically significant results. The first was a gender 3 time interaction (Chi = 8.060, P = 0.045). Females and males had similar rates of abnormal SGOT values at baseline (18.8% and 16.7%, respectively); however, females had significantly lower rates of abnormal values than males during days 71-98 (10.0% of females vs. 34.3% of males, Chi = 6.800, P = 0.009). The second significant result was a medication 3 time interaction (Chi = 8.852, P = 0.037). Buprenorphine treated subjects' rate of abnormal SGOT values rose from pretreatment to days 71-98 (12.0% to 31.2%, Chi = 1.520, P = 0.218) while the methadone group's abnormal rates remained steady from baseline to days 71-98 (22.5% to 20.9%, Chi = 1.960, P = 0.162). However, within group comparisons across time were not statistically significant. In addition, there was no significant difference between medications for rates of abnormal values at baseline or during days 71-98. For SGPT results, there was no medication or time effect; however, there was a significant gender effect. Males had overall higher rates of abnormal test results than females (males: 27.5% vs. females: 20.3%, Chi = 5.570, P = 0.018).
There were no significant main effects or interactions for medication, gender, or time for alkaline phosphatase when results were analyzed.
Retained Sample
Although there were no clinically significant results for total protein, total bilirubin, albumin, or globulin as demonstrated by the infrequent rate of abnormal test values (5 total) among the 86 subjects who completed the study, PROC MIXED showed several statistically significant results. There were medication by gender interactions for total protein (F = 4.210, P = 0.044) and globulin (F = 5.680, P = 0.020), and main effects of medication (F = 6.500, P = 0.013) for total protein. Albumin test results had main effects of gender and time (F = 13.010, P = 0.001 and F = 3.040, P = 0.034, respectively), and total bilirubin test results had a gender effect (F = 5.160, P = 0.026). Figure 1 shows changes over time by medication and gender for the 3 other LFTs-SGOT, SGPT, and alkaline phosphatase. While there were no significant effects for alkaline phosphatase, and no difference between medication assignments for SGOT and SGPT values, there were significant gender effects for both SGOT and SGPT. 
Additional LFT Analyses
Ninety subjects (48 taking buprenorphine and 42 taking methadone) had normal baseline SGOT values, and of this sample 39.6% (n = 19) of the buprenorphine subjects, and 26.2% (n = 11) of the methadone subjects developed an abnormal SGOT value during treatment. These proportions were not significantly different by medication (P = 0.262) 2), P = 0.866), or the proportion that returned to normal at later time points while still taking study medication (buprenorphine: 36.8% (n = 7) vs. methadone: 27.3% (n = 3), P = 0.702). There were also no significant differences by medication (P = 0.353) or by gender (P = 0.117) in the development of an abnormal SGPT value. Seventeen of 43 subjects taking buprenorphine (39.5%) and 11 of 40 subjects taking methadone (27.5%) developed an abnormal SGPT test while taking study medication. Of subjects who developed newly elevated SGPT values during treatment, there were no differences between medications in the day in treatment of the first detected abnormal value (buprenorphine mean (S.D.): 69.7 (32.6) vs. methadone mean (S.D.): 52.9 (18.7), P = 0.095), and again the range was wide for both medications (buprenorphine: days 32-126 and methadone: days 27-86). There was also no difference between medications in the average abnormal value (u/l; buprenorphine (S.D.): 182.5 (159.9) vs. methadone mean (S.D.): 258.9 (275.0), P = 0.746), the change from baseline to peak abnormal SGPT value (u/L; buprenorphine (S.D.): 139.0 (163.8) vs. methadone mean (S.D.): 260.1 (429.3), P = 0.817), or the proportion that returned to normal at later time points while still taking study medication (buprenorphine: 29.4% (n = 5) vs. methadone: 36.4% (n = 4), P = 1.000).
The last LFT analysis examined subjects who had abnormal SGOT or SGPT results at baseline and at least 1 other SGOT or SGPT test value (abnormal or not) while taking study medication, to determine if medication 1 Gender effect (F = 4.00, P = 0.049). 2 Gender effect (F = 5.66, P = 0.020). .7), P = 0.205). In addition, there was no difference in the proportion of subjects by medication that had SGPT tests normalize while continuing on study medication (buprenorphine: 30.8% (n = 4) vs. methadone: 25.0% (n = 3), P = 1.000).
Lofwall et al ADDICTIVE DISORDERS & THEIR TREATMENT
Symptom Checklist
In general, subject rated weekly side effect scores for items on the Symptom Checklist were low across the 16 weeks of maintenance treatment. Ten items (trouble urinating, trouble swallowing, tremors/shaking, skin rash, ringing in the ears, heart racing, dreaming more while asleep, dizziness/faintness, diarrhea, and blurred vision) had average values for medication assignment and gender that were less than 1 (ie, average ratings between none and mild in intensity). Only 1 item (constipation) had mean values of greater than 2 (ie, moderate intensity) by both medication and gender. Thirteen items decreased significantly in score intensity over time (constipation, nausea, loss of interest in sex, dry mouth, often thirsty, upset stomach, vomiting, groggy or sleepy after medication, trouble swallowing, tremors/shaking, heart racing, dizziness/faintness, and diarrhea). The 3 symptoms with the highest average values (constipation, loss of interest in sex, and nausea) are shown in Figure 2 .
Constipation scores (left panel, Fig. 2 ) were significantly higher in women and in subjects taking buprenorphine, peaked earlier in methadone subjects (week 2) than buprenorphine subjects (week 3), and peaked twice in buprenorphine females (week 2 and week 12), producing significant main effects of medication and gender, and significant medication 3 week and medication 3 gender 3 week interactions. Loss of interest in sex (middle panel, Fig. 2 ) was significantly higher in women and decreased in intensity significantly later for women. Nausea (right panel, Fig. 2 ) was significantly higher in the buprenorphine group.
Buprenorphine treated subjects also had higher symptom ratings than methadone treated subjects for heart racing, often thirsty, dry mouth, ringing in the ears, blurred vision, skin rash, trouble swallowing, and dizziness/faintness (although still low in overall severity). Five other symptoms had significant gender or gender 3 week effects, with females reporting higher symptom scores and taking longer to report decreases in symptom intensity (vomiting, groggy or sleepy after medication, skin rash, often thirsty, and blurry vision). Significant medication 3 gender interactions were found for symptoms of skin rash, dizziness/faintness, ringing in the ears, trouble swallowing, and blurred vision where buprenorphine treated females reported higher symptom intensities than other groups. Lastly, there were 3 symptoms (groggy or sleepy after medication, vomiting, and blurred vision) with significant medication 3 gender 3 week interactions, with buprenorphine treated females reporting multiple peaks of symptom intensities throughout the 16 week maintenance period for these 3 items.
Vital Signs
Retained Plus Drop-Out Sample Abnormally low results were infrequent (less than 1%) across all time intervals for each measure, and there were no significant differences between medication or gender on rates of low results across time intervals. There were no significant differences by gender for abnormally elevated vital sign data, so results for elevated values are summarized in Table 4 by medication group and time in treatment.
Fewer than 10% of study participants registered an abnormal high value for any vital sign while taking either study medication. Results for each measure showed no pattern suggesting one medication was associated with a greater frequency of elevations at any one of the time periods. Rates of abnormal diastolic blood pressure decreased for both medications from pre-admission assessment to in treatment study periods resulting in a significant time effect (Chi = 13.640, P = 0.034).
Retained Sample
Mean vital sign results by medication and gender (buprenorphine males, buprenorphine females, methadone males, methadone females) were within normal limits (Table 2) at each time point: mean systolic blood pressure was less than 125 mm Hg, mean diastolic blood pressure was less than 82 mm Hg, mean heart rate was less than 82 beats/min, and mean respiratory rate was less than 21 breaths/min. There were no mean vital sign results by medication and gender that fell below the lower limits of normal. 
Medical Reports
A total of 27 medical reports were completed for 19 subjects (12 reports for 11 patients assigned to the buprenorphine condition and 15 reports for 8 patients assigned to the methadone condition). Problems noted on medical reports were categorized and are summarized in Table 5 . More than 1 concern per subject report was frequently noted.
As shown in the right-hand column of Table 5 , the most common problems reported were nausea (7 notations), vomiting (6 notations), constipation (4 notations), rash (4 notations), elevated LFTs (3 notations), and headache (3 notations). Overall, problems were generally equally rated for both buprenorphine and methadone as being possibly or probably related to study medications (as shown in the column totals at the bottom of Table 5 ).
Ratings of severity of problems were made by the double-blind medical staff. For the 27 reports, there were 9 rated as mild, 15 rated as moderate, and 3 rated as severe. The 3 reports with severe ratings were for 2 methadone patients and 1 buprenorphine patient, and contained 7 items: vomiting, thirsty, dreaming, and constipation (for the methadone patients), and shortness of breath, swollen extremities, and foot pain (for the buprenorphine patient). A review of the individual items showed no pattern suggesting a specific medication-related effect.
DISCUSSION
This comparative clinical trial of buprenorphine and methadone for the outpatient treatment of opioid dependence provided the opportunity to systematically and prospectively compare the side effect and safety profiles of these two medications. The flexible dosing procedure helped ensure equally effective doses of both medications as demonstrated by comparable efficacy across a broad array of outcome measures, 5, 21 and limits confounding of the present data by dose differences between medications. This report longitudinally assessed over 16 weeks liver function, vital signs, self-reports of side effects, and medical reports of patient complaints. Overall, the present results demonstrate buprenorphine and methadone produce similar profiles on these measures of safety and side effects. In addition, gender effects were minimal and had little clinical significance. Because the liver metabolizes both buprenorphine and methadone, chronic treatment with these medications increases concern about the potential for liver toxicity. This concern is heightened because opioid dependent persons have high baseline rates of liver function abnormalities that could be potentially exacerbated by hepatically metabolized medications. Clinical studies of methadone maintenance subjects have not found methadone to be associated with liver toxicity. [16] [17] [18] [19] [20] A few reports have found elevated LFTs, specifically SGOT and SGPT, in buprenorphine maintained persons, 12, 14 particularly in those with hepatitis B and/or C. 13 However, there were no non-buprenorphine comparison groups in these studies, making it difficult to determine if buprenorphine was the cause for these reported elevations. The present study provides evidence that rates of abnormal LFTs and absolute values of LFTs for buprenorphine are not significantly different from those seen with methadone. Abnormal values were infrequent for several LFTs (total protein, albumin, globulin, and total bilirubin), but were more frequent for SGOT and SGPT across both medications. The high rates of abnormal SGOT and SGPT values throughout treatment is consistent with an early study in heroin dependent persons that compared rates of abnormal SGOT and SPGT tests before and after 10 years of methadone treatment. Abnormal rates at baseline and 10 years later were 65% and 80% for SGOT, and 56% and 31% for SGPT, respectively. 18 There was no evidence in that study that methadone caused the abnormally elevated SGOT and SGPT values. Likewise, in this study although rates of abnormal SGOT and SGPT values increased over time in the buprenorphine group, this was not significantly different from the change in abnormal rates across time for the methadone group. Nevertheless, studies examining liver function over longer periods of buprenorphine maintenance should be conducted to determine whether this trend for increasing values continues or stabilizes. Analyses of rates of newly abnormal SGOT and SGPT test results demonstrated no medication or gender effects. Approximately one-third of SGOT or SGPT values became abnormal during treatment with both buprenorphine and methadone, and approximately one-third returned to normal at subsequent time points while in treatment which is consistent with previous work. 18 Despite this high rate of newly abnormal tests, there were only 3 medical reports made for abnormal LFTs. All 3 were in the methadone group, rated as either mild or moderate in severity, and not rated by the blind physician as related to study medication. One retrospective study suggests that it is not buprenorphine alone that causes increases in SGOT and SGPT test values, but the additional presence of hepatitis B and/or C. 13 We were not able to serologically confirm diagnoses of hepatitis B or C in our sample, but we were able to evaluate the course of SGOT and SGPT values in subjects with abnormal baseline SGOT and SGPT values, a group that may be vulnerable to further increases in these LFTs. Results for both SGOT and SGPT values demonstrated mean decreases or no significant increases for both medications, and approximately one-third of subjects' abnormal baseline values returned to normal while taking either study medication. These findings are in contrast to those from earlier work assessing LFTs in buprenorphine maintained subjects. 13 The small sample size in this present analysis could have limited the power to detect significant differences between the two medications. Further evaluation of the comparative effects on liver function of buprenorphine and methadone using a prospective study design in a larger sample among patients with infectious hepatitis or other vulnerabilities to liver dysfunction is needed. Overall, these LFT results do not indicate that abnormal values are preferentially induced by buprenorphine or methadone, in either those with or without baseline normal test values. These elevations could be related to other factors commonly occurring within a drug using lifestyle, including infectious diseases, toxic effects of illicit drugs, chronic alcohol exposure, tumors, and exposure to environmental toxins. Viral hepatitis and alcohol abuse are particularly common in this patient population. 19, [25] [26] [27] [28] [29] Additionally, abnormal SGOT and SGPT results were detected throughout the study period, indicating there is not one particular period while taking medication during which the liver appears vulnerable. This may support the idea that other causative factors outside of medication play an important role in the production of these abnormal test results. Thus, the finding that buprenorphine and methadone do not produce significantly different effects on LFTs is reassuring given that methadone is a medication known not to be hepatotoxic. However, because methadone carries no While LFTs provide an important biologic assessment for adverse effects of medications, patients' self-reports of side effects also provide valuable information about the acceptability of a medication. Results from the Symptom Checklist showed that patients of both genders and in both medication conditions tended to report low intensity effects that generally decreased over time. Interestingly, the pattern of these effects for several symptoms did differ for buprenorphine versus methadone, with patients receiving buprenorphine reporting greater symptoms than patients receiving methadone. While for most measures differences between buprenorphine and methadone tended to diminish over time, with ratings essentially indistinguishable by the final weeks of treatment, ratings of constipation remained elevated for patients on buprenorphine relative to patients on methadone throughout the 16 weeks of the study (Fig. 2) . However, there were only 4 medical reports regarding constipation (Table  5) , and these 4 reports were evenly divided between the buprenorphine and methadone conditions. Thus, while average ratings of constipation were higher for patients in the buprenorphine condition, this did not result in a greater proportion of buprenorphine patients seeking medical consultation regarding this symptom.
Differences between medications and genders in side effect profiles are intriguing. This could reflect patients' greater familiarity with the side effects of methadone, or a differential rate of habituation to the side effects of methadone versus buprenorphine. While several of the gender effects seen in this study were statistically significant, these generally were not clinically meaningful since these symptom intensities were rated as 1 (mild) or less by the end of treatment and infrequently mentioned in medical reports.
A review of other problems noted on the medical reports showed no pattern of a differential profile of effects for buprenorphine versus methadone (Table 5) . Rates for most reported problems were very low, and almost evenly divided between buprenorphine (23 problems) and methadone (28 problems). Furthermore, only about one-half of problems were rated as possibly or probably being related to the study medication, and the majority of problems were rated as mild or moderate (not severe). While these medical reports only occurred in response to a patient seeking out consultation from the medical staff, their results provide further evidence that there was not a marked difference between medications in patient concerns about adverse effects of their medication, nor a detectable difference between medications in side effects noted by the medical staff.
Participants also had vital sign assessments at 2-week intervals during the first 12 weeks of the study, and then once per month for the remainder of their time in treatment. There were no significant differences between the two medication conditions in the rates of abnormal systolic blood pressure, diastolic blood pressure, heart rate, temperature, or respiratory rate (Table 4) . While female gender was associated with lower systolic and diastolic pressure, and also with higher temperatures, the mean values for both males and females were within normal range. Abnormally low measures were extremely rare, while rates for abnormally high values were also quite low for all vital signs.
The set of assessments reported in this paper provides important data about the safety and tolerability of buprenorphine as a medication for the treatment of opioid dependence. However, these results also provide valuable information about the safety and tolerability of methadone. Thus, results for the methadone condition may be useful in interpreting abnormal test results and patient reports of side effects. In addition, the present data can function as useful comparison rates of abnormal test results for future pharmacotherapy studies for the treatment of substance abuse disorders. Notably, this study used buprenorphine sublingual solution while the formulation approved for the treatment of opioid dependence in the U.S. is the combination buprenorphine/naloxone sublingual tablet. Although orally administered naltrexone, an opioid antagonist similar to naloxone, has been associated with elevated LFTs at high doses, 30 it has not been hepatotoxic at doses normally used for treating opioid dependence. 31 Sublingual naloxone has poor bioavailability, 32 making it unlikely that the addition of naloxone to buprenorphine tablets will produce different effects on the safety and side effect profiles reported here. However, this may not be the case if the tablet is dissolved and injected parenterally where naloxone has higher bioavailability. This is an important area for future investigation as sublingual buprenorphine has been abused parenterally, [33] [34] [35] [36] and injection abuse is associated with adverse effects on liver function. 11 If there are additive or synergistic adverse effects of naloxone with buprenorphine on liver function or other biologic functions, this would be important public health information. The primary purpose of this study was to assess the relative safety of buprenorphine and methadone for the treatment of opioid dependence. While there has been extensive work examining the efficacy of buprenorphine, there has been relatively little data on its safety and side effects, in particular effects on liver function, in comparison to other opioid agonist medications. The present results provide important evidence, from both objective measures of adverse effects as well as patient self-reports of side effects, that buprenorphine is safe and produces a mild side-effects profile. In addition, there is little evidence from these data that buprenorphine is associated with elevated LFTs, in either producing new liver function elevations or exacerbating preexisting abnormal test values. Thus, these results, together with results from other studies, show that buprenorphine is a safe medication for the treatment of opioid dependence.
